Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report issued on Monday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. William Blair reaffirmed an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. Leerink Partners set a $20.00 price objective on shares of Tenax Therapeutics in a research note on Monday, March 10th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Trading Up 0.4 %

TENX opened at $5.45 on Monday. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $7.89. The company has a market cap of $21.64 million, a P/E ratio of -1.02 and a beta of 1.88. The company’s 50 day moving average is $6.26 and its 200-day moving average is $5.63.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.34. On average, equities analysts forecast that Tenax Therapeutics will post -0.88 EPS for the current year.

Hedge Funds Weigh In On Tenax Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP purchased a new stake in shares of Tenax Therapeutics in the 4th quarter worth $84,000. Geode Capital Management LLC increased its stake in Tenax Therapeutics by 32.4% during the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after acquiring an additional 5,964 shares during the last quarter. Millennium Management LLC purchased a new position in Tenax Therapeutics during the fourth quarter worth $166,000. Finally, Janus Henderson Group PLC bought a new position in shares of Tenax Therapeutics during the fourth quarter valued at approximately $1,026,000. 1.67% of the stock is currently owned by hedge funds and other institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.